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1. Introduction
The gametes are highly specialized haploid cells that harbor genetic background of each in‐
dividual. During fertilization, the fusion of female and male gametes occurs in order to pro‐
duce zygote. These zygotes are diploid cells and have genetic material of both individuals.
Zygotes start to divide and undergo further pre-implantation development through the for‐
mation of morula, blastocysts and finally fetus (Fig. 1). When intrauterine fetal development
is finished, the organism is already formed and ready to birth. The zygotes can be consid‐
ered primordial stem cells, which originate the whole organism through unequal divisions
to produce blastomeres, the cells resulting by cleavage of a zygote. Sixteen blastomeres con‐
stitute a morula, the spherical embryonic mass surrounded by the zona pellucid, which fur‐
ther became a blastocyst. Blastocyst is a thin-walled hollow structure surrounded by
trophoblasts layer that contains a cluster of cells called the inner cell mass (ICM) from which
the embryo arises and the scientists isolate embryonic stem (ES) cells for in vitro cultivation
and for study the process of differentiation. However, ES cells are pluripotent cells able to
produce any cell type raise ethical concerns about the destruction of human embryo to pro‐
duce stem cell lines. To get the better concept of pluripotent cells for stem cell based thera‐
pies the reprogramming of patient specific adult cells to embryonic stage was suggested
(Takashi & Yamanaka,2006). Cell reprogramming is a process of de-differentiation of somat‐
ic cells into pluripotent state whereby they adopt features of ES cells. De-differentiation of
adult cells can be achieved through i. somatic cell nuclear transfer; ii. cell fusion - somatic
cell hybrids and; iii. production of induced pluripotent stem (iPS) cells through the activa‐
tion of essential stemness genes (reprogramming factor), over-expression in fibroblasts
and/or other adult cells. Small molecules and other technologies are also exploring to repro‐
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gram cells without the use of viral vectors primarily by Yamanaka. The methods used for
cell de-differentiation induce the expression of genes that are not normally expressed in
adult cell but are expressed in pluripotent stem cells, leading to the activation of pluripotent
cell transcriptional networks. A cascade of transcriptional activity switch on the changes in
gene expression profile in the adult cells, which begins to express a repertoire of genes that
are commonly, identified in pluripotent ES cells. Following reprograming the adult cells un‐
dergo morphological changes and begin to grow as a tightly packed cluster of cells known
as a colony, which mirrors how undifferentiated ES cells grow in culture. Both processes of
reprograming and resulting pluripotency of reprogrammed cells vary significantly and elu‐
cidation of different approaches can clarify the reprograming process. In this chapter we
will describe different methods of reprogramming of differentiated cells to pluripotent cells
and the knowledge gain from each. Additionally, we try to provide a functional vision on
reprogramming process and to analyze different types of stem cell niches produced by natu‐
ral and reprogrammed cells. The better comprehension of stem cell niches will allow us to
improve the reprogramming technology and to put more close in production of natural plu‐
ripotent stem cells using molecular biology approaches.
Figure 1. Early development of stem cells niches. According to current knowledge there are natural stem cells niches
during development: morula, blastocyst, epiblast and fetus, and artificial stem cells niches: stem cell culture in vitro.
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2. Natural in vivo pluripotent stem cell niches
2.1. Morula stem cell niche
Here we proposed that starting from morula, when zona pellucid arises, a first specific com‐
partment called stem cell niche is formed. This niche can be defined as a microenvironment
in which stem cells are found. Stem cell niche provides the both interaction between the cells
and their interaction with local microenvironment, by which their fate regulates and occurs.
In morula, stem cell niche consists of pluripotent stem cells that provide expression of spe‐
cific transcription factor, such as POU domain transcription factor (Oct3/4) responsible for
self-renewal capacity and pluripotency of these cells. In mammals morula first cell fate deci‐
sions is governed by key transcriptional factor: Oct3/4 (Palmieri et al., 1994). Oct3/4 is
unique because it requires maintaining the pluripotency in both conditions in vivo and in vi‐
tro (Nichols et al., 1998) and it is essential for epigenetic reprogramming (Niwa et al., 2000).
The depletion of transcription factors leads to increased expression of genes that are in‐
volved in the processes of development and cell differentiation (Niwa et al., 2000).
2.2. Blastocyst stem cell niche
The first lineage segregation is resulted in the formation of trophectoderm and ICM (Wobus,
et al., 2005). Upon silencing of Oct3/4, a part of morula cells spontaneously inactivates the
self-renewal process and start to differentiate into trophoblast cells, thus forming pluripo‐
tent stem cell niche in blastocyst. This blastocyst niche is a dynamic structure which follows
developmental program of an organism in parallel with Oct3/4, expression of other tran‐
scriptional factor such as Nanog occurs in ICM. in early blastocyst (Nichols et al., 1998; Avi‐
lon et al., 2003).
2.3. Epiblast stem cell niche: Naive and primed pluripotent stem cells
In mice in late blastocyst transcription factor Sox2 starts to express in the cells of ICM in ad‐
dition to GATA6 and Nanog, which lead to formation of two distinct populations: epiblast
and hypoblast (Mitsui et al., 2003). These cell populations are considered the precursors of
the primitive endoderm and the pluripotent epiblast (Morrissey et al., 1998). Recent studies
suggest that stem cells in rodent epiblast have two distinct stable states of pluripotency: na‐
ïve and primed, thus establishing epiblast stem cell niche (Tesar et al., 2007; Nichols, 2009).
According to these classification both of states exhibit features of bona fide pluripotent stem
cells, such as have indefinite self-renewal, tri-germ layer potential and depend on expres‐
sion of all three transcription factors, such as Oct3/4, Sox2 and Nanog (Tesar et al., 2009;
Nichols, 2009; de Los Angeles et al., 2012). Naïve (more immature) pluripotent stem cells
can be obtained from pre-implanted stage of embryo in rodents (Okamoto et al., 2003).
These cells have both sex X chromosomes activated and are able to produce high-grade chi‐
meras after their reintroduction into the host blastocyst. In contrast, in humans primed plu‐
ripotent ES cells are isolated from human pre-implantation blastocysts stage of
development. In these cells one of female X chromosome is inactivated, albeit human ES
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cells are self-renewing and express key transcription factors and are able to form teratoma
(Okamoto et al., 2003; Brons et al., 2007; Tesar et al., 2005). Studies of X chromosome inacti‐
vation in pre-implantation human embryos reported that XIST transcript accumulation on
this chromosome occurs in the eight-cell stage embryo, however the identity of the cells,
which show XIST accumulation is not clear. In vitro studies of XIST accumulation in human
ES cells lines revealed three different patterns of X chromosome inactivation. The naïve state
- with both active X chromosomes, intermediate state - with both XIST accumulation and
last - state, when the cells never undergo X chromosome inactivation even under differentia‐
tion and XIST accumulation does not occur (Dvash and Fan, 2009). Therefore, using current
technologies “true” pluripotent stem cells can be exclusively isolated from mouse and may
be from some other rodents, which present similar pattern of early embryonic development
with mice. It is not obvious if it is possible to obtain “true” human ES cells, once we cannot
test their contribution into developing human embryo (due to ethic consideration). Howev‐
er, the lack of X chromosome reactivation indicates that probably these cells will never be
able to reintegrate into early development events in vivo similar to rodent.
3. In vitro pluripotent stem cell niches
After isolation, pluripotent stem cells start to organize in vitro stem cell niche, which up to a cer‐
tain degree simulates experience of these cells in vivo. In vitro these cells showed similar mor‐
phology with ICM, forming islands of juxtaposed cells and expressing pluripotent stem cell
markers such as Oct3/4, Nanog, Sox2 (Tesar et al., 2005; Tesar et al., 2007). However, to distin‐
guish in vitro naïve and primed pluripotent cells are difficult or even impossible task due to
high heterogenety of pluripotent cell lines established in vitro (Brons et al., 2007; Tesar et al.,
2007). Different factors may contribute to this heterogeneity, such as natural polymorphism of
the cells, selection of colonies in vitro, which can be pluripotent at different degrees, cell cul‐
ture conditions adopted in each work as well as pluripotent cells, itself, may produce an “im‐
perfect” in vitro microenvironment again due to their natural heterogeneity.
4. Generation of artificial pluripotent stem cell – Reprogramming
strategies
4.1. Reprogramming by means of differentiated cells nuclear transfer
Several strategies can be provided in order to reprogramming differentiated or committed
somatic cell genome. One of these strategies is a nuclear transfer (NT) of differentiated cell
nucleus to oocyte whose maternal DNA was removed (Campbell et al., 1996). This type of
reprogramming uses the natural components without any previous genetic or molecular
modification of nucleus–donor and oocyte-recipient. NT is relatively efficient and frequently
depends on technical experience of researcher (Galli et al., 2012). There are two kinds of nu‐
clear transfer trial: egg-NT involves the transfer of a single somatic nucleus to an unfertil‐
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ized enucleated oocyte and oocyte-NT involves the transplantation of multiple somatic cell
nuclei into immature oocyte of amphibian. Nevertheless are important differences between
the two types of nuclear transfer experiment. In oocyte-NT experiments extensive cell divi‐
sion take places and new functional cell types appear as soon as the nuclear transplant em‐
bryo start to develop. In this experiment somatic cell chromatin is directly reprogrammed to
express pluripotency genes within a day. In contrast to oocyte-NT experiments, in egg-NT
no new cell types are formed, and neither oocyte nor nuclei divide, however direct transi‐
tion of reprogrammed nuclei that transcribe genes of pluripotency into differentiated cells
occurs. Analysis of the mechanism of reprogramming in egg-NT experiments, which in‐
volves transcription pluripotency genes and others, is complicated owing to rapid DNA rep‐
lication and numerous cell divisions (Halley–Scott et al., 2010; Julien et al., 2010).
The NT process leads to direct reprogramming of pluripotent stem cell and expression of
such markers as Oct3/4, Nanog, and Sox2 that are silent in differentiated somatic cell nu‐
cleus. In general, the reactivation of silent pluripotency genes starts around 24 and 48 hours
after NT (Halley–Scott et al., 2010; Julien et al., 2010; Byrne et al., 2003). Upon NT occurs the
series of events when oocyte cytoplasm induces changes in the structure of donor chromatin
toward pluripotent state, which became more appropriate for embryonic development.
However, synchronization process which should happen between genomic DNA of donor
cell and cytoplasm of recipient cell is complex and may affect significantly pluripotency of
reprogrammed cells. Attempts to facilitate this reprogramming process have been made us‐
ing chemicals that alter the methylation status of the chromatin, such as TSA (trichostatin
A), azacytidine, scriptaid, either before or after NT. In the mouse, the use of TSA (a histone
deacetylase inhibitor, HDACi) significantly increased the success rate of mouse cloning
(Kishigami et al., 2007).
Figure 2. Stages of nuclear transfer. The nucleus is removed from an egg (or oocyte) and replaced by a nucleus from a
donor cell (somatic cell).
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In mammals, embryo obtained by NT and transferred into foster mother can result (or not)
in full term development. The clones, obtained by NT method, are genetically identical to
donor organism, which provide a nucleus. The sheep Dolly was the first successfully cloned
farm animal. Dolly was obtained from NT of terminally differentiated mammary epithelial
cell (Campbell et al., 1996). However the generation of animals by NT is not very efficient,
once many clones are dying soon after implantation, and only few clones survive and born
(Galli et al. 1999; Ritchie 2006). These clones frequently affected with severe abnormalities,
they die prematurely and often obese. The survival rate of clones depends on species, on do‐
nor cell type, method of NT and varied significantly between different laboratories (Oback
& Wells, 2002; Wilmut et al., 2002). However, pre-implantation development does not seem
to be a problem (Ono et al., 2001; Ono et al., 2001a) the majority of the term losses occurs
during the post implantation period and/or after birth. It has been reported in some experi‐
mental studies, that only 2-3% of the transferred embryos develop to term in mice (Ono et
al., 2001a; Sakai et al., 2005). Over time the methods were improved and other species have
been cloned with success from differentiated donor cells, such as cattle (Galli et al., 1999);
mouse (Wakayama & Yanagimachi, 1999); pig (Polejaeva et al., 2000a); cat (Shin et al., 2002);
goat (Keefer et al., 2002); mule (Woods et al., 2003); horse (Galli et al., 1999); rabbit (Challah-
Jacques et al., 2003); rat (Zhou et al., 2003) and dog (Lee et al., 2005). In humans, the attempt
to NT has been achieved using animal oocytes as recipients for human genetic material. The
reprogramming of human somatic cell nuclei did not occur after NT into bovine and rabbit
oocytes. These oocytes with human genome were not able to follow early embryonic devel‐
opment. The up-regulation of human pluripotency-associated genes did not occur. These
data raised a question about the potential use of animal embryonic environment to generate
patient-specific stem cells using NT technology. Ethical implications also should be taken in
consideration (Chung et al., 2009).
4.2. Reprogramming by means of stem cells nuclear transfer
In 1998, Cibelli performed stem cells nuclear transfer (SCNT) using nucleus of bovine fibro‐
blasts and enucleated bovine oocytes. They obtained 330 reconstructed oocytes, generated
37 cloned blastocysts, which served for isolation of 22 ES-like cell lines. These ES-like cells
were injected into bovine oocytes, cultured cultured to produce embryos that further which
were transferred into recipient females. In six out of seven calves at least one tissue originat‐
ed from ES cell has been found. Other authors demonstrated the ability of karyoplast of ES
cells induce Oct4 expression in the somatic genome (Tada, 2001).
In humans (Hall et al., 2007) and non-human primate (Mitalipov et al., 2002) the SCNT effi‐
ciency of blastocyst formation has typically been very low, thus suggesting a lack in or com‐
plete nuclear reprogramming. In order to overcome these difficulties modified SCNT
approach was used to produce rhesus macaque blastocysts from adult skin fibroblasts and
to isolate from this blastocyst two ES cell lines. This was achieved thought non-invasive ap‐
proaches for meiotic spindle detection in oocytes and their removal using high-performance
imaging. Spindle imaging system supports rapid and highly efficient real-time enucleation
of primate oocytes. In this experiment spindle removal efficiency was 100%. The investiga‐
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tion of karyotype, microsatellite and single nucleotide polymorphisms (SNP) analyses con‐
firmed that both ES cell lines were originated from SCNT embryos and were not from
parthenotes. These ES cell lines demonstrated typical pluripotent cells morphology, self-re‐
newal capacity and expression of stem cell markers. They were also transcriptionally similar
to ES cells derived from fertilized blastocysts, and pluripotent, as demonstrated by the gen‐
eration of several tissues from three germ layers after in vivo teratoma formation (Byrne
2007). Additionally, the experiments using mouse pluripotent primordial germ (PG) and ES
cells as nuclei donors have also been performed using single-cell NT method. The results
showed that embryos obtained from PG or ES cells NT method cannot develop and com‐
plete pre-implantation stage (Kato and Tsunoda, 1995). Possibly that long term in vitro cul‐
ture can affect the karyotype of these cells accumulating chromosomal abnormalities, thus
resulting in formation of abnormal embryos (Balbach et al., 2007).
The main goal of NT technology was to multiply the genotypes of high genetic value in farm
animals and species, which are under the risk of extinction. Further, this technology was
used as a tool for genome reprogramming of somatic differentiated cells into pluripotent
state. The principles of cloning, which were developed by Willadsen (1986), are also impor‐
tant today. All the cloning studies provided the first experimental evidence for reprogram‐
ming (Kono et al., 1997; Gurdon, 2008). Currently, NT technologies can be applied in two
different ways, to produce animal clones and to reprogram the nuclei of differentiated so‐
matic cell, which can be used for basic research to analyze X chromosome inactivation or to
study the dynamics of imprinting process during reprogramming and in some cases for pre-
clinical evaluation of these cells in animal models (Hochedlinger and Jaenisch 2006). This
technology yet holds medical interest to produce patient-specific stem cells, which can be
used in cell therapy and regenerative medicine.
4.3. Reprogramming by means of early embryonic environment
The pluripotency, characteristic feature of ES cells, can be evaluated by their capacity to dif‐
ferentiate into cells of the three germ layers. More precisely, ES cells pluripotency can be
evaluated by generation of chimaeras, organisms composed of cells from two or more indi‐
viduals from the same or different species (Kaufman, 1981; Keller, 1995; Wobus, 2005). Pro‐
duction of human/animal chimaeras is a method currently in use to analyze developmental
potency of mammalian ES in biomedical research (Behringer, 2007; Lensch et al., 2007).
James et al (2006) showed for the first time that a nonhuman embryo surrogate environment
could be used to study developmental potential of human ES cells as well as biological com‐
patibility between human ES cells and the mouse ICM. Adult stem cells (ASC) are now seen
as an alternative to ES cells, which can raise a number of ethical objections due requires de‐
struction of human embryo. Populations of multipotent ASC that express ES cell markers,
such as Oct3/4, Nanog and Sox2, presenting a differentiation capacity similar to that of ES
cells in vitro, can be isolated from different fetal and adult animal and human tissues (Wen‐
ceslau et al., 2011). For example, we have reported the isolation of human immature dental
pulp stem cells (hIDPSC) from deciduous (baby) teeth, which express the aforementioned
pluripotent markers and can differentiate into several cell types in vitro, such as bone, carti‐
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lage, skeletal, smooth muscles and neurons (Kerkis et al., 2006; Lizier et al., 2012). We found
that after their transplantation into adult mice, they engrafted within different mouse or‐
gans, such as the liver, heart, spleen, kidney and the brain. Although hIDPSC express pluri‐
potent cell markers they present fibroblast-like morphology and were isolated from adult
tissues (Kerkis et al., 2006; Lizier et al., 2012). We demonstrated that hIDPSC are truly multi‐
potent cells, which were able to undergo further development similar to mouse ES cells in
nonhuman embryo surrogate environment. These cells were able to contribute in vitro into
ICM of mouse blastocyst, thus undergoing cell divisions, and in vivo into fetus development
thus generating pretermed human/mouse chimaera, which a prerequisite to characterizing
pluripotency similar for ES cells. In this study in order to analyze the ability of hIDPSC (46,
XY) to contribute to ICM and trophectoderm of mouse early embryos, 6–8 cells stained with
vital Vibrant fluorescent dye (Fig. 3A) were injected into the perivitelline space and/or the
blastocell of 8 compacted morulae and 20 early blastocysts (Fig. 3B). After injection these
cells have adopted similar size to those of the recipient mouse embryo. They proliferated in
the recipient mouse embryonic environment and showed a contribution to the ICM and also
to the trophoblast cell layer (Fig. 4A). To determine the developmental and pluripotent ca‐
pacity of hIDPSC, six to eight stained cells were injected into the blastocele of 57 early blas‐
tocysts (Fig. 4B) and were immediately transferred to the uterus of five foster mothers. Three
mice achieved pregnancy and, according to ethical recommendations, human/mouse chi‐
maeras were collected before birth. The 18 d.p.c. mouse foetuses seemed to be well formed
based on their morphological appearance (Fig. 4C).
Figure 3. The hIDPSC injection in early embryonic environment. (A) hIDPSC stained with vital Vibrant fluorescent dye
were injected into the perivitelline space and/or compacted morulae (B) hIDPSC showed a contribution to the ICM
and also to the trophoblast cell layer.
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Additionally to Vibrant fluorescent dye the anti-hIDPSC antibody, (this identifies exclusive‐
ly hIDPSC), was used to detect the presence of these cells in 18 d.p.c. mouse foetuses).
Strong fluorescent signals were observed in different organs of the chimaeras, such as the
brain, liver, intestine and muscles (Fig. 4D and Fig. 5B). Using a variety of methods we dem‐
onstrated hIDPSC contribution to mouse embryos, which did not present any type of mor‐
phological deficiency (Fig. 5A). We were able to produce evidence, that these cells
accomplished differentiation within local tissues, by the presence of human-specific tissue
proteins, such as myosin and cytokeratin. Moreover, we used a specific antibody against hu‐
man nuclei to confirm, again, that the cells were indeed of human origin (Siqueira da Fonse‐
ca et al., 2009). Little is known about the initial reprogramming events that occur after
transference of ASC into mouse blastocysts (Yokoo et al., 2005). In our experiment, hIDPSC
were capable of engrafting and proliferating inside mouse morulae and blastocysts and
forming pretermed chimaeras. These cells contributed not only to ICM, as do human ES
cells, but also to the trophoblast cell layer – without any embryo damage.
Figure 4. Developmental and pluripotent capacity of hIDPSC to generating pretermed human/mouse chimaera. Early
chimera blastocyst (A) were transferred to the uterus of foster mother (B). Human/mouse chimaeras (C) were collect‐
ed before birth and fluorescent signals were observed in different organs of the chimaeras (D).
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Furthermore, hIDPSC integrated into host embryos and developed foetuses, undergoing the
process of differentiation. Obviously that due to the difference in cell cycle dynamics be‐
tween mouse and human cells, the number of human cells during mouse pre-natal develop‐
ment is decreased in comparison with hIDPSC contribution in ICM of blastocyst. However,
it is not clear if hIDPSC can really undergo reprogramming into ES-like cells within nonhu‐
man embryo surrogate environment.
Our finding suggests that expression of such pluripotent markers, as nanog and oct4 by
hIDPSC is enough condition for these cells to contribute into different mouse tissues in early
embryo-fetal development, to differentiate properly and to express human proteins within
mouse fetal an immune privileged environment (Siqueira da Fonseca et al., 2009).
Figure 5. The hIDPSC contribution in pretermed human/mouse chimaera. (A) 18 d.p.c. mouse fetus. (B) Strong fluores‐
cent signals were observed in different organs of the chimaeras, such as the brain, liver, intestine, muscles and others.
4.4. Reprogramming by means of cell fusion
First pluripotent hybrid cells have been isolated by fusion of pluripotent teratocarcinoma
(TC)  cells  with  differentiated somatic  cells,  which served as  a  tool  for  investigating the
interaction between different genomes. These TC cells are similar to ES cells in morphol‐
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ogy and gene expression pattern, thus maintaining variable levels of pluripotency, how‐
ever  not  all  TC  cells  able  to  generate  chimaeras  and  to  contribute  to  germ  line
(Papaioannou and Rossant  1983).  These  cells  frequently  have abnormal  karyotype,  such
as  loss  of  the  Y  chromosome,  trisomy,  deletions  or  translocations  (Takagi  et  al.  1983,
Rousset et al. 1983, Modlinski et al. 1990). The hybrid cells obtained from pluripotent TC
cells  and somatic  cell  partner,  which express  embryonic  antigens,  were able  to  produce
teratomas containing derivatives of all three embryonic germ layers (Andrews and Good‐
fellow 1980, Atsumi et al.,  1982; Rousset et al. 1983; Forejt et al.,  1984; Takagi, 1983) and
to  form embryoid bodies  (EBs)  in  suspension culture  (Takagi,  1983).  These  hybrid  cells
showed  also  reactivation  of  particular  genes  after  reprogramming  (Miller  and  Ruddle,
1976, 1977; Andrews and Goodfellow, 1980; Rousset et al., 1983) and reactivation of inac‐
tive X chromosome originated from the somatic partner (McBurney and Adamson, 1976;
McBurney and Strutt, 1980; Takagi et al., 1983, Takagi, 1988; Mise et al., 1996). However,
pluripotent  hybrids  were  obtained  when  lymphocytes  or  thymocytes,  not  fibroblasts,
were used as the somatic parents in fusion (Rousset et  al.,  1979).  These studies indicate
that  hybrid  cells  generated  by  ES  cells  and  differentiated  cells,  which  have  less  cyto‐
plasm, seem to be more adequate systems to undergo reprogramming.
Matveeva et al. (1996) has obtained cultures of intraspecific embryonic hybrid cells by fusion
of mouse ES cells, denominated HM-1 cells, which were derived from HPRT-deficient strain
129 mice (Magin et al., 1992) and characterized as highly pluripotent (Magin et al., 1992;
Selfridge et al.1992) with splenocytes derived from an adult DD/c female. These hybrids
were denominated as hybrid embryonic stem and somatic (HESS) cells and characterized as
pluripotent and HPRT positive (Matveeva et al., 1996; 1998). Our group used three mouse
hybrid clones HESS-1, HESS-2 and HESS-3 in order to study their karyotypes and investi‐
gate the influence of the karyotypes on the differentiation of these cells through the forma‐
tion of embryonic bodies (Mittmann et al., 2002). The hybrid cells used in our study were
near diploid (HESS-2 and HESS-3) and near tetraploid (HESS-1) and chromosome analysis
showed different trisomies. The trisomies of chromosomes 1 and 11 were found in near dip‐
loid hybrids. These trisomies are probably typical of these pluripotent cells, and have previ‐
ously been described in the mouse ES cells line (Crolla et al., 1990) and in TC cells
(McBurney and Rogers, 1982). We found that the sex chromosome constitution in the
HESS-2 line was predominantly XY, while in the HESS-3 line it was XO. Interesting that in
HESS-2 and HESS-3 lines the segregated X chromosome was of embryonic origin. Indeed, it
has been demonstrated by Ringertz and Savage (1976) that hybrids lose the chromosomes
originating from differentiated, more slowly dividing cells. In our experiments, hybrids
showed the capacity to form EBs in vitro, even at late passages (Fig. 6). The EBs formed by
the hybrid cells could be considered as complex as those derived from the HM-1 line and
the cystic-type EBs formed by pluripotent cells (Martin and Evans, 1975; Van der Kamp et
al., 1984; Doetschman et al., 1985; Pease et al., 1990).
In the EBs derived from hybrids we observed haematopoietic-like cells,  cells  resembling
skeletal  and  smooth  muscle  and  others  (Fig.  7).  Cells  of  ectodermal  origin  (e.g.  nerve
cells) were not identified in EBs derived from hybrids. Our data shows that the ‘embry‐
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onic’  X chromosome may be lost  in pluripotent  hybrids,  but  reprogramming of  the ‘so‐
matic’  X chromosome may still  occur,  thus allowing restricted pluripotency. The normal
karyotype may be a prerequisite for the efficient contribution of  these cells  to the germ
line in transgenic and chimeric animals and for their ability to differentiate in vitro into a
wide spectrum of cell  types (Papaioannou et  al.,  1978;  McBurney Rogers,  1982;  Pease et
al.,  1990; Bronson et al.,  1995; Liu et al.,  1997; Suzuki et al.,  1997).  Therefore, we further
tested the capacity of near diploid HESS-2 to differentiate in vitro  in putative germ cells
(GC) (Fig. 8). We demonstrated that two days after induction of differentiation by retino‐
ic acid, the HESS-2 derived GC-like cells presented expression patterns of a gene set, in‐
volved  in  the  progression  of  early  stages  of  gametogenesis  (Vasa,  Stella,  Dazl,  Piwil  2,
Tex14, Bmp8b, Tdrd1 and Rnf17).  This finding is similar to previous descriptions of GC
obtained in vitro  from mouse ES cells (Hübner et al.,  2003; Geijsen et al.,  2004; Kerkis et
al.,  2007).  HESS-2  generates  GC in  vitro,  which were  able  to  differentiation into  sperm-
and oocyte-like  cells.  These  structures  resembling the formation of  presumptive oocytes
appeared floating in the culture medium. FISH analyses indicate that several GC derived
from HESS-2 hybrid cells  were able to undergo sex chromosome reduction.  The expres‐
sion of ZP2 and ZP3, oocyte-specific markers, was also detected supporting our morpho‐
logical  observation.  Hence our observations indicate that  HESS-2 cells  can progress into
both female- and male- GC differentiation, however,  the female developmental program
could be achieved only in early stages (Lavaginolli et al., 2009).
Figure 6. Cystic embryoid body - a globular cell cluster cultured from mouse ES cells.
Therefore, we demonstrated that near diploid somatic cell hybrids obtained by the fusion of
ES cells with differentiated cell can be fully reprogrammed and able to produce in vitro even
GCs. It is not likely that these cells will be able to generate live offspring after fertilization of
normal oocyte due to abnormal karyotype. However, they represent an interesting model to
study the influence of karyotype on the process of GC in vitro formation. More recently the
reprograming of somatic cell nucleus after the fusion with induced pluripotent stem (iPS)
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cells has been reported (Takahashi and Yamanaka, 2006). These iPS-somatic cell hybrids
demonstrated the expression of markers of pluripotent cells, such as Oct4, SSEA-1, and alka‐
line phosphatase and were able to differentiate into multiple cell types similar to ES cells,
thus confirming the reprogramming ability of iPS cells (Takahashi and Yamanaka, 2006).
Figure 7. Electron microscopy demonstrates differentiation within cystic embryoid bodies derived from somatic cell
hybrids (HESS-2).
Figure 8. Germ cell derived in vitro from HESS-2. (A) Protocol of differentiation. (B) Expression of genes involved in the
progression of early stages of gametogenesis during HESS-2 differentiation. (C) Sperm-like structure. (D) Oocyte-like
structure. (E and F) Haploid cells with X or Y chromosomes. (G) Expression of oocyte-specific markers in oocyte-like
structures obtained from HESS-2.
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4.5. Reprogramming by means of Yamanaka’s factors
The pluripotency manifests during short time of early mammalian development (Choen et
al., 2011; Dejosez et al., 2012). Such powerful, pluripotent cells can be obtained in vitro from
early embryo and they are very promising for the future of regenerative medicine and even
for organ generation. However, in humans isolation of these cells implicates with ethical
problem of embryo destruction. Thus the idea to obtain such pluripotent cells artificially
took the minds of the researchers. The technologies to obtain such alternative pluripotent
cells are growing continuously. Yamanaka 's group using the combination of different fac‐
tors performed the first reprograming of mouse embryonic fibroblasts. The resulted iPS cells
showed gene-protein expression of ES-cell markers, teratoma formation, differentiation into
the tissues of three germ layers, beside chimaeras generation. This reprogramming strategy,
using defined factors (i.e. Klf4, Oct4, Sox2, and c-Myc, termed “KOSM”), is conceptually and
technically simple (Takahashi & Yamanaka, 2006). However, it is a low efficient and repro‐
ducibility process, which is influenced by several variables and also could affect the quality,
such as completely or non-completely reprogrammed iPS cells. These variables are the age
donor, cell type, different delivery systems and reprogramming cocktail choice, factors used
for reprogramming (Daley et al., 2009). Currently, several strategies, based on genes, pro‐
teins, iRNA, as well as on different chemicals, are available for the reprogramming of somat‐
ic cells (Nakagawa et al., 2008; Yu et al., 2007). In the original method of iPS generation
developed by Yamanaka’s group used the moloney murine leukemia virus (MMLV) retrovi‐
rus for transgene expression (Takahashi and Yamanaka 2006). This vector has cloning ca‐
pacity of around 8 kb allows delivery of genes into the genome of cells and expected to be
silenced after reprogramming and induction of endogenous genes activation. The efficiency
of iPS cells generated using MMLV retroviruses Expressing the KOSM set genes is around
0.1% in mouse embryonic fibroblasts and approximately 0.01% in human fibroblasts (Jahner
et al., 1982; Stewart et al., 1982; Hotta et al., 2008). Lentiviral vector is also used in reprog‐
raming experiments thus exhibiting slightly higher (8–10 kb) cloning capacity and usually
have higher infection efficiency than MMLV retroviruses (Blelloch et al., 2007). However,
carcinogenesis may be caused by genomic integration of retro- or lentiviral fragments into
host DNA (Varas et al., 2009) and use of c-Myc oncogene, which after reactivation might
cause malignant tumor formation (Okita et al., 2007; Brambrink et al., 2008). Thus viral sys‐
tems are still unsafe for therapeutic application. Therefore, a number of reports demon‐
strates that iPS cells can be generated by reducing the use of viral constructs and/or
minimize viral integration through substitution of key reprogramming factors by chemical
compounds or employing less differentiated cells, which already express endogenously one
or more of the key pluripotency factors (Hota et al., 2008). Our group reprogrammed
hIDPSC-fibroblast-like cells isolated from deciduous (baby) teeth, which express endoge‐
nous Oct3/4 and Nanog, using retroviral vector and four Yamanaka’ s factors (Fig. 9).
Reprogrammed hIDPSC presented all key characteristics of pluripotent cells: formed juxta‐
posed colonies of ES-like morphology and produce teratoma with derivates of all three germ
layers. These cells did not integrate retroviral vector in their genome and express lower lev‐
els of Oct4, Nanog and Sox 2. In contrast to iPS cells derived to fibroblast cell, the hIDPSC
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derived iPS cells were generated to in shorter time and presented higher efficiency of colo‐
nies formation And were able to form under iPS colonies feeder –free conditions conditions.
For example, the time of fibroblasts reprogramming using retrovirus vectors takes 20–25
days (Aesen et al., 2008), while reprogramming of hIDPSC occurs only in eleven days after
infection (Beltrão-Braga, 2011). These results suggest that age of donor and differentiation
status of cell type used for reprograming may also affect reprogramming efficiency. Accord‐
ingly, Maherali and Hochedlinger et al., (2007) compared skin fibroblasts reprograming effi‐
ciency from two-month-old and two years-old mice. Older cells produced half as many iPS
cell colonies as young skin fibroblasts. It has been shown that iPS cells have so-called epige‐
netic memory, which means that after reprograming their differentiation potential can re‐
flect on their lineage commitment before reprograming. Therefore, hIDPSC showed strong
neural commitment, which is due to their ectomesodermal origin. After reprograming
strong neural commitment was evidenced within teratomas as well as spontaneous in vitro
differentiation into neurons hIDPS-iPSC was also detected. It was expected that ordinary
human adult cells reprogrammed as iPSC may revolutionize medicine by creating new
therapies unique to individual patients. However, important questions have persisted about
the safety of these cells, such as it is not clear the degree to which these cells are homologous
to ES cells in respect of the genes expression pattern, differentiation capacities, epigenetics
and in particular interest is the question whether iPSCs genetic material is altered during the
reprogramming process. The researchers, which examined 22 different human iPSC lines
obtained from seven research groups showed that these cells present 10 times more muta‐
tions than they expected to find. While some of the mutations appeared to be silent, the ma‐
jority did change specific protein functions, including those in genes associated with
causative effects in cancers. Anyway, the studies of iPSC provide an important new tool in
the fight against human disease, but to use these cells directly in the clinic, we must ensure
that they are safe.
Figure 9. hIDPSC-derived iPS cell. (A) Representative figure of morphological characteristics of hIDPSC in vitro cultur‐
ing. (B) iPS cell derivation were shown to be obtained under feeder-free condition on matrigel-coated dishes. (C) A
typical hIDPSC-derived iPS cell colony. Light microscopy.
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5. Final considerations
All reprogramming strategies are aimed at genomic reprogramming, which is a key biologi‐
cal process. It is still unknown, how many and what reprogramming factors, which initiate a
cascade of reprogramming events, are involved in NT, SCNT, in cell fusion and even in iPS
cell production. Yamanaka’s study suggests that these factors may be mainly proteins of the
nucleus; however the cytoplasm factors also should be taken in consideration. NT techni‐
que, which was used for Dolly the Sheep and many other species, has been abandon by
many researches due to the low efficiency. Some researches try to use SCNT in stem cells
research in order to obtain stem cells that are genetically matched to the donor organism.
However, up to data no human ES cells were obtained using SCNT. Another limitation of
this method is that resulting cells retain mitochondrial structures, which originally belonged
to the egg. The great limitation of cell fusion technology is chromosome set composed by
different genomes. Currently many scientists, which used all these methods moved to iPS
cell production.
We started this chapter with simplified description of the concept of stem cell niches for‐
mation during early development. This conception lead to comprehension that such nich‐
es are very complex and composed by heterogeneous population of different somatic and
stem cells. We know, that at least two different populations of pluripotent stem cells na‐
ïve and prime can be identified in vivo  and isolated in vitro  in rodents. In humans these
two populations are difficult to identified and isolate.  Additionally, the data on the pat‐
tern of X chromosome activation of in vitro cultured human ES cells suggest the existence
of may be three such populations. In adult organism the number of stem cell  niches in‐
creased  dramatically,  the  examples  are  neuronal,  hematopoietic,  hair  follicle,  skeletal
muscle,  dental  pulp and many other  stem cells  niches.  In  order  to  obtain  stem cells  of
the most excellent quality the scientist try to re-create stem cell niche in vitro, which ena‐
bles  ad of  control  of  culture conditions,  including oxygen tension and hydrostatic  pres‐
sure  and  various  factors  believed  to  be  involved  in  self-renewing,  division,  migration,
recruitment and lineage commitment of stem cells.  Any strategies of reprogramming are
closely related with the conception of stem cell niche, because in all strategies of reprog‐
ramming the nucleus or the cell  with different developmental  histories and from differ‐
ent cells niches are used. In order to translate the potential of reprogrammed cells into to
the  clinical  reality  our  knowledge  about  reprogrammed  stem  cells  microenvironment
should be significantly improved.
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